SUMO2P18

Across TCGA pan-cancer cohorts, SUMO2P18 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SUMO2P18’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SUMO2P18 RNA is repressed in tumor relative to normal tissue. In most cancer types SUMO2P18 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

THCA, BRCA, and ESCA are the cancer types where SUMO2P18 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SUMO2P18 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	All	−0.185	<.001	7	view →
BRCA	Female	All	−0.071	.016	6	view →
ESCA	All	II,III,IV	+0.300	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

SUMO2P18–THCA

Open the THCA breakdown →